文献速递甲状腺疾病

美国妊娠期亚临床甲状腺功能减退症治疗实践差异:全国性评估

Variation in Treatment Practices for Subclinical Hypothyroidism in Pregnancy: US National Assessment.
PubMed 文献 · J Clin Endocrinol Metab · 2019-01-01

本研究基于美国大型行政索赔数据库的回顾性队列,纳入7990例未治疗时TSH 2.5-10 mIU/L的妊娠期亚临床甲状腺功能减退症(SCH)女性,仅15.2%接受左甲状腺素(LT4)治疗。治疗启动与临床医生专科、基线TSH、患者因素及美国地区相关,内分泌科医生在更低TSH阈值即启动治疗。

要点

  • 妊娠期SCH女性中仅15.2%接受LT4治疗,多数符合治疗条件者未治疗。
  • 内分泌科医生较其他专科在更低TSH阈值启动LT4,且治疗对象更多有复发性妊娠丢失和甲状腺疾病。
  • LT4治疗启动与地理区域、临床医生专科及患者特征相关。

核心结论

  • 妊娠期SCH女性LT4处方存在较大差异,多数符合治疗条件者仍未治疗。
  • 治疗启动与地理、临床医生及患者特征相关,可指导质量改进。

研究设计与样本

  • 回顾性队列研究,使用美国大型行政索赔数据库。
  • 纳入7990例妊娠期SCH女性,定义为未治疗TSH 2.5至10 mIU/L。

主要发现

  • 7990例中仅1214例(15.2%)接受LT4治疗。
  • TSH较高、肥胖、复发性妊娠丢失、甲状腺疾病及由内分泌科医生照护者更可能接受治疗。
  • 接受治疗女性比例随时间增加,2014年LT4治疗可能性是2010年的两倍。
  • 美国东北部和西部女性较其他地区更可能接受LT4。
  • 与白人女性相比,亚裔女性更可能、西班牙裔女性更不可能接受LT4。

临床怎么用

  • 临床应关注妊娠期SCH治疗不足的现状,尤其非内分泌科照护及部分地域和族裔人群。
  • 内分泌科医生在更低TSH阈值启动LT4的实践差异提示需统一治疗标准。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

CONTEXT: Although thyroid hormone replacement may improve outcomes in pregnant women with subclinical hypothyroidism (SCH), the extent to which they receive treatment is unknown. OBJECTIVE: To describe levothyroxine (LT4) treatment practices for pregnant women with SCH. DESIGN: Retrospective cohort study. SETTING: Large US administrative claims database. PARTICIPANTS: Pregnant women with SCH defined by untreated TSH 2.5 to 10 mIU/L. MAIN OUTCOME MEASURE: Initiation of LT4 as a function of treating clinician specialty (endocrinology, obstetrics/gynecology, primary care, or other), baseline TSH, patient clinical and demographic factors, and US region. RESULTS: We identified 7990 pregnant women with SCH; only 1214 (15.2%) received LT4. Treatment was more likely in patients with higher TSH, obesity, recurrent pregnancy loss, thyroid disease, and cared for by endocrinologists. Proportion of treated women increased over time; LT4 treatment was twice as likely in 2014 as in 2010. Women in Northeast and West US were more likely to receive LT4 compared with other regions. Asian women were more likely, whereas Hispanic women were less likely, to receive LT4 compared with white women. Endocrinologists started LT4 at lower TSH thresholds than other specialties, and treated women who were more likely to have had recurrent pregnancy loss and thyroid disease than women treated by other clinicians. CONCLUSIONS: We found large variation in the prescription of LT4 to pregnant women with SCH, although most treatment-eligible women remained untreated. Therapy initiation is associated with geographic, clinician, and patient characteristics. This evidence can inform quality improvement efforts to optimize care for pregnant women with SCH.

来源:J Clin Endocrinol Metab,查看原文。版权归原作者所有。

引用

  1. Maraka S, Mwangi R, Yao X, et al. Variation in Treatment Practices for Subclinical Hypothyroidism in Pregnancy: US National Assessment. J Clin Endocrinol Metab. 2019. PMID: 31127823. doi:10.1210/jc.2019-00057

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。